

Edgar Filing: MEDIFAST INC - Form 10-Q

MEDIFAST INC
Form 10-Q
August 14, 2006

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES
EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2006

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES
EXCHANGE ACT OF 1934

For the transition period from _____ to _____

Commission file number 0-23016

MEDIFAST, INC.
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)

DELAWARE
(STATE OR OTHER JURISDICTION
OF ORGANIZATION)

13-3714405
(I.R.S. EMPLOYER
IDENTIFICATION NO.)

11445 CRONHILL DRIVE
OWINGS MILLS, MD 21117
TELEPHONE NUMBER (410) 581-8042

Indicate by checkmark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes No

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of "accelerated filer and large accelerated filer" in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer Accelerated filer Non-accelerated filer

Indicate by checkmark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes No

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date.

OUTSTANDING AT JULY

Edgar Filing: MEDIFAST INC - Form 10-Q

CLASS

27, 2006

Common stock, \$.001 par value per share

13,519,481 shares

1

Index

PART I

FINANCIAL INFORMATION:

Condensed Consolidated Balance Sheets - June 30, 2006 (unaudited) and December 31, 2005 (audited).....	3
Condensed Consolidated Statements of Income - Three and Six Months Ended June 30, 2006 and 2005 (unaudited).....	4
Condensed Consolidated Statements of Cash Flows - Six Months Ended June 30, 2006 and 2005 (unaudited).....	5
Notes to Condensed Consolidated Financial Statements.....	7
Management Discussion and Analysis of Financial Condition and Results of Operations.....	13

PART II

Exhibits.....	18
EX 31.1	
EX 31.2	
EX 32.1	

2

MEDIFAST, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS

	June 30, 2006 (Unaudited)
ASSETS	
CURRENT ASSETS:	
Cash	\$ 2,491,000
Accounts receivable-net of allowance for doubtful accounts of \$100,000	717,000
Inventory	6,698,000
Investment securities	2,773,000
Deferred compensation	567,000
Prepaid expenses and other current assets	2,776,000

Edgar Filing: MEDIFAST INC - Form 10-Q

Prepaid taxes	311,000
Note receivable - current	230,000
Deferred tax asset	90,000

TOTAL CURRENT ASSETS	16,653,000
Property, plant and equipment - net	10,822,000
Trademarks and intangibles - net	4,768,000
Deferred tax asset, net of current portion	256,000
Note receivable, net of current portion	1,351,000
Other assets	37,000

TOTAL ASSETS	\$ 33,887,000
	=====
LIABILITIES AND STOCKHOLDERS' EQUITY	
CURRENT LIABILITIES:	
Accounts payable and accrued expenses	\$ 3,480,000
Income taxes payable	-
Line of credit	615,000
Current maturities of long-term debt	533,000
Deferred tax liability - current	-

TOTAL CURRENT LIABILITIES	4,628,000
Long-term debt, net of current portion	3,729,000
Deferred tax liability - non-current	-

TOTAL LIABILITIES	8,357,000

STOCKHOLDERS' EQUITY:	
Common stock; par value \$.001 per share; 20,000,000 authorized; 13,422,914 and 12,782,791 shares issued and outstanding, respectively	14,000
Additional paid-in capital	25,897,000
Accumulated other comprehensive income	139,000
Retained Earnings	4,300,000

	30,350,000
Less: cost of 215,061 and 210,902 shares of common stock in treasury	(1,135,000)
Less: unearned compensation	(3,685,000)

TOTAL STOCKHOLDERS' EQUITY	25,530,000

TOTAL LIABILITIES & STOCKHOLDERS' EQUITY	\$ 33,887,000
	=====

See accompanying notes to condensed consolidated financial statements.

Edgar Filing: MEDIFAST INC - Form 10-Q

MEDIFAST, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF INCOME

	SIX MONTHS ENDED JUNE 30, 2006 (Unaudited)	2005 (Unaudited)	
Revenue	\$ 39,137,000	\$ 18,881,000	\$ 1
Cost of sales	9,629,000	4,696,000	
	-----	-----	
GROSS PROFIT	29,508,000	14,185,000	1
Selling, general, and administration	23,913,000	12,119,000	1
	-----	-----	
INCOME FROM OPERATIONS	5,595,000	2,066,000	
Other income/(expense)			
Interest expense	(181,000)	(148,000)	
Loss on sale of Consumer Choice Systems	(323,000)		
Stock compensation expense	(181,000)	-	
Interest income	89,000	97,000	
Other income (expense)	161,000	3,000	
	-----	-----	
INCOME BEFORE PROVISION FOR INCOME TAXES	5,160,000	2,018,000	
Provision for income tax (expense)	(2,009,000)	(758,000)	
	-----	-----	
NET INCOME	3,151,000	1,260,000	
Less: Preferred stock dividend requirement	-	-	
	-----	-----	
NET INCOME	\$ 3,151,000	\$ 1,260,000	\$
	=====	=====	=====
Basic earnings per share	\$ 0.25	\$ 0.10	
Diluted earnings per share	\$ 0.23	\$ 0.10	
Weighted average shares outstanding -			
Basic	12,603,903	12,173,456	1
Diluted	13,601,232	12,858,777	1

See accompanying notes to condensed consolidated financial statements.

Edgar Filing: MEDIFAST INC - Form 10-Q

	Six Months Ended June 2006 (Unaudited)	2005 (Unaudited)
Cash flows from operating activities:		
Net income	\$ 3,151,000	\$ 1,151,000
Adjustments to reconcile net income to net cash provided by operating activities from continuing operations:		
Depreciation and amortization	1,262,000	1,262,000
Realized (gain) loss on investment securities	(49,000)	(49,000)
Loss on sale of Consumer Choice Systems	323,000	323,000
Common stock issued for services	49,000	49,000
Stock options vested during period	18,000	18,000
Excess tax benefits from share-based payment arrangements	(6,000)	(6,000)
Vesting of unearned compensation	181,000	181,000
Net change in other comprehensive (loss) income	(143,000)	(143,000)
Deferred income taxes	(119,000)	(119,000)
Provision for bad debts	-	-
Changes in assets and liabilities:		
(Increase) decrease in accounts receivable	137,000	137,000
(Increase) in inventory	(1,581,000)	(1,581,000)
(Increase) decrease in prepaid expenses & other current assets	497,000	497,000
(Increase) in deferred compensation	(42,000)	(42,000)
(Increase) in prepaid taxes	(311,000)	(311,000)
(Increase) decrease in other assets	(55,000)	(55,000)
Increase in accounts payable and accrued expenses	1,217,000	1,217,000
(Decrease) in deferred tax liability	(418,000)	(418,000)
(Decrease) in income taxes payable	(899,000)	(899,000)
Net cash provided by operating activities	<u>3,212,000</u>	<u>1,151,000</u>
Cash Flow from Investing Activities:		
(Purchase) of investment securities, net	(25,000)	(25,000)
(Purchase) of property and equipment	(1,737,000)	(1,737,000)
(Purchase) of intangible assets	(409,000)	(409,000)
Net cash provided by (used in) investing activities	<u>(2,171,000)</u>	<u>(1,171,000)</u>
Cash Flow from Financing Activities:		
Issuance of common stock, options and warrants	254,000	254,000
Increase in credit line, net	(18,000)	(18,000)
Principal repayments of long-term debt	(276,000)	(276,000)
Excess tax benefits from share-based payment arrangements	6,000	6,000
Dividends paid on preferred stock	-	-
Net cash provided by (used in) financing activities	<u>(34,000)</u>	<u>(34,000)</u>
NET INCREASE IN CASH AND CASH EQUIVALENTS	1,007,000	1,007,000
Cash and cash equivalents - beginning of the period	<u>1,484,000</u>	<u>1,484,000</u>
Cash and cash equivalents - end of period	\$ 2,491,000	\$ 1,484,000

Edgar Filing: MEDIFAST INC - Form 10-Q

Supplemental disclosure of cash flow information:		
Interest paid	\$ 181,000	\$
Income taxes	\$ 2,977,000	\$ 1
Supplemental disclosure of non cash activity:		
Common stock issued to executives over 6-year vesting period	\$ 3,373,000	\$
Common shares issued for options and warrants	\$ 384,000	\$
Options vested during period	\$ 18,000	\$
Conversion of preferred stock B and C to common stock	\$ -	\$
Common stock issued for services	\$ 49,000	\$
Preferred B and C stock dividends converted to common stock	\$ -	\$
Line of credit converted to long-term debt	\$ -	\$

See accompanying notes to condensed consolidated financial statements.

5

MEDIFAST, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (CONT.)

	Six Months Ended June 30,	
	2006	2005
	(Unaudited)	(Unaudited)
Supplemental disclosure of non cash activity:		
Sale of Consumer Choice Systems		

Inventory	\$ 358,000	\$ -
Accounts Receivable	131,000	-
Intangible assets, net	1,337,000	-
Note receivable	(1,503,000)	-
Loss on sale of Consumer Choice Systems	(323,000)	-
	-----	-----
	\$ -	
	=====	=====

See accompanying notes to condensed consolidated financial statements.

6

Edgar Filing: MEDIFAST INC - Form 10-Q

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

GENERAL

1. Basis of Presentation

The condensed unaudited interim consolidated financial statements included herein have been prepared, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. The condensed consolidated financial statements and notes are presented as permitted on Form 10-Q and do not contain information included in the Company's annual statements and notes. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations, although the Company believes that the disclosures are adequate to make the information presented not misleading. It is suggested that these condensed consolidated financial statements be read in conjunction with the December 31, 2005 audited consolidated financial statements and the accompanying notes thereto. While management believes the procedures followed in preparing these condensed consolidated financial statements are reasonable, the accuracy of the amounts are in some respects dependent upon the facts that will exist, and procedures that will be accomplished by the Company later in the year.

These condensed unaudited consolidated financial statements reflect all adjustments, including normal recurring adjustments, which, in the opinion of management, are necessary to present fairly the operations and cash flows for the period presented.

2. Presentation of Financial Statements

The Company's condensed consolidated financial statements include the accounts of Medifast, Inc. and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated.

3. Inventories

Inventories consist principally of finished packaged foods, packaging and raw materials held in either the Company's manufacturing facility and distribution warehouse. Inventories are valued with cost determined using the first-in, first-out (FIFO) method.

4. GOODWILL AND OTHER INTANGIBLE ASSETS

In June 2001, the Financial Accounting Standards Board ("FASB") issued Statement No. 142 "Goodwill and Other Intangible Assets". This statement addresses financial accounting and reporting for acquired goodwill and other intangible assets and supersedes APB Opinion No. 17, "Intangible Assets". It addresses how intangible assets that are acquired individually or with a group of other assets (but not those acquired in a business combination) should be accounted for in financial statements upon their acquisition. This Statement also addresses how goodwill and other intangible assets should be accounted for after they have been initially recognized in the financial statements. On January 17, 2006, the Company sold its goodwill balance of \$893,500 when the Consumer Choice Systems division was sold.

The Company has intangible assets, which include: customer lists, non-compete agreements, trademarks and patents. The non-compete agreements are being amortized over the legal life of the agreements ranging between 3 to 7 years.

Edgar Filing: MEDIFAST INC - Form 10-Q

The customer lists are being amortized over a period ranging between 5 to 10 years based on management's best estimate of the expected benefits to be consumed or otherwise used up. Trademarks and patents are regularly reviewed to determine whether the facts and circumstances exist to indicate that the useful life is shorter than originally estimated or the carrying amount of the assets may not be recoverable. The Company assesses the recoverability of its trademarks and patents by comparing the projected discounted net cash flows associated with the related asset, over their remaining lives, in comparison to their respective carrying amounts. Impairment, if any, is based on the excess of the carrying amount over the fair value of those assets.

7

	AS OF JUNE 30, 2006		AS OF
	GROSS CARRYING AMOUNT	ACCUMULATED AMORTIZATION	GROSS CARR AMOUNT
Customer lists	\$ 4,555,000	\$ 1,269,000	\$ 4
Non-compete agreements	840,000	745,000	
Trademarks and patents	1,485,000	98,000	1
Goodwill	-	-	
	-----	-----	-----
Total	\$ 6,880,000	\$ 2,112,000	\$ 8

AMORTIZATION EXPENSE FOR THE SIX MONTHS ENDED JUNE, 2006 AND 2005 WAS AS FOLLOWS:

	2006
Customer lists	\$
Non-compete agreements	
Trademarks and patents	

Total Trademarks and Intangibles	\$

On January 17, 2006 the Consumers Choice Systems division of the Company was sold which included the sale of \$1,601,000 in gross intangible assets and \$265,000 in accumulated amortization.

Amortization expense is included in selling, general and administrative expenses.

5. Fixed Assets

Edgar Filing: MEDIFAST INC - Form 10-Q

Fixed assets are stated at cost. Depreciation is provided using the straight-line method over the estimated useful lives of the related assets, which are generally three to seven years. Leasehold improvements and equipment under capital leases are amortized on a straight-line basis over the lesser of the estimated useful life of the asset or the related lease terms. Expenditures for repairs and maintenance are charged to expense as incurred, while major renewals and improvements are capitalized.

8

6. Note Receivable

Medifast realized a \$1,503,000 note receivable as a result of the sale of Consumer Choice Systems on January 17, 2006 to a former board member. The note has a 10-year term with imputed interest of 4% collateralized by 50,000 shares of Medifast stock and all the assets of Consumer Choice Systems. The amount of principal to be collected over each of the next 5 years is \$183,000 per year with the remaining amount collectible thereafter of \$588,000.

7. Income Per Common Share

Basic income per share is calculated by dividing net income by the weighted average number of outstanding common shares during the year. Basic income per share excludes any dilutive effects of options, warrants and other stock-based compensation.

8. Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.

9. Share Based Payments

Stock-Based Compensation

Effective December 31, 2005, the Company adopted the provisions of Financial Accounting Standards Board Statement of Financial Accounting Standard ("SFAS") No. 123(R), "Share-Based Payments," which establishes the accounting for employee stock-based awards. Under the provisions of SFAS No.123(R), stock-based compensation is measured at the grant date, based on the calculated fair value of the award, and is recognized as an expense over the requisite employee service period (generally the vesting period of the grant). The Company adopted SFAS No. 123(R) using the modified prospective method and, as a result, periods prior to December 31, 2005 have not been restated. The Company recognized stock-based compensation for awards issued under the Company's stock option plans in other income/expenses included in the Condensed Consolidated Statement of Operations. Additionally, no modifications were made to outstanding stock options prior to the adoption of SFAS No. 123(R), and no cumulative adjustments were recorded in the Company's financial statements.

Prior to December 31, 2005, the Company accounted for stock-based compensation in accordance with provisions of Accounting Principles Board Opinion No. 25 ("APB No. 25"), "Accounting for Stock Issued to Employees," and related interpretations. Under APB No. 25, compensation cost was recognized based on the

Edgar Filing: MEDIFAST INC - Form 10-Q

difference, if any, on the date of grant between the fair value of the Company's stock and the amount an employee must pay to acquire the stock. The Company grants stock options at an exercise price equal to 100% of the market price on the date of grant. Accordingly, no compensation expense was recognized for the stock option grants in periods prior to the adoption of SFAS No. 123(R).

Unearned compensation represents shares issued to executives that will be vested over a 5-6 year period. These shares will be amortized over the vesting period in accordance with FASB 123(R). The expense related to the vesting of unearned compensation was \$181,000 and \$0 at June 30, 2006 and June 30, 2005, respectively.

9

SFAS No. 123(R) requires disclosure of pro-forma information for periods prior to the adoption. The pro-forma disclosures are based on the fair value of awards at the grant date, amortized to expense over the service period. The following table illustrates the effect on net income and earnings per share as if the Company had applied the fair value recognition provisions of SFAS No. 123, "Accounting for Stock-Based Compensation", for the period prior to the adoption of SFAS No. 123(R), and the actual effect on net income and earnings per share for the period after the adoption of SFAS No. 123(R).

	Six Months Ended	
	06/30/06	06/30/05
Net income, as reported	\$ 3,151,000	\$ 1,260,000
Add: Stock-based employee compensation expense included in reported net income, net of related tax effects	11,000	-
Deduct: Total stock-based employee compensation expense determined under fair value based method for all awards, net of related tax effects	(11,000)	-
Net income, pro forma	\$ 3,151,000	\$ 1,260,000
Earning per share:		
Basic, as reported	0.25	0.10
Basic, pro forma	0.25	0.10
Diluted, as reported	0.23	0.10
Diluted, pro forma	0.23	0.10

For the purpose of the above table, the fair value of each option granted is estimated as of the date of grant using the Black-Scholes option-pricing model with the following assumptions:

Six Months Ended

Edgar Filing: MEDIFAST INC - Form 10-Q

	June 30, 2006	June 30, 2005
Dividend yield	0.0%	0.0%
Expected volatility	0.70	0.70
Risk-free interest rate	4.50%	4.5%
Expected life in years	1-5	1-5

10

The following summarizes the stock option activity for the Six Months ended June 30, 2006:

	June 30, 2006		
	Shares	Weighted Average Exercised Price	Weighted Average Contractual Term (Years)
Outstanding, December 31, 2005	284,727	1.51	
Options granted	100,000	6.25	
Options reinstated	16,666	6.36	-
Options exercised	(39,813)	(2.52)	
Options forfeited or expired	(20,000)	9.88	
Outstanding June 30, 2006	341,580	4.12	3.78
Options exercisable, June 30, 2006	214,913	3.16	3.25
Options available for grant at end of year	965,273		

10. Recent Accounting Pronouncements

In December 2004, the Financial Accounting Standards Board ("FASB") issued Statement of Financial Accounting Standards ("SFAS") No. 151, "Inventory Costs." SFAS No. 151 requires abnormal amounts of inventory costs related to idle facility, freight handling and wasted material expenses to be recognized as current period charges. Additionally, SFAS No. 151 requires that allocation of fixed production overheads to the costs of conversion be based on the normal capacity of the production facilities. The standard is effective for fiscal years beginning after June 15, 2005. The adoption of SFAS No. 151 did not have a material impact on the Company's financial position or results of operations.

In May 2005, the FASB issued SFAS No. 154, "Accounting Changes and Error Corrections." SFAS No. 154 replaces Accounting Principles Board ("APB") Opinion

Edgar Filing: MEDIFAST INC - Form 10-Q

No. 20, "Accounting Changes" and SFAS No. 3, "Reporting Accounting Changes in Interim Financial Statements." SFAS No. 154 requires retrospective application to prior periods' financial statements of a voluntary change in accounting principle unless it is impracticable. APB No. 20 previously required that most voluntary changes in accounting principle be recognized by including the cumulative effect of changing to the new accounting principle in net income in the period of the change. SFAS No. 154 is effective for accounting changes and corrections of errors made in fiscal years beginning after December 15, 2005. The adoption of SFAS No. 154 did not have a material impact on the Company's financial position or results of operations.

In February 2006, the FASB issued SFAS No. 155, "Accounting for Certain Hybrid Financial Instruments, an amendment of FASB Statements No. 133 and 140." SFAS No. 155 resolves issues addressed in SFAS No. 133 Implementation Issue No. D1, "Application of Statement 133 to Beneficial Interests in Securitized Financial Assets," and permits fair value remeasurement for any hybrid financial instrument that contains an embedded derivative that otherwise would require bifurcation, clarifies which interest-only strips and principal-only strips are not subject to the requirements of SFAS No. 133, establishes a requirement to evaluate interests in securitized financial assets to identify interests that are freestanding derivatives or that are hybrid financial instruments that contain an embedded derivative requiring bifurcation, clarifies that concentrations of credit risk in the form of subordination are not embedded derivatives and amends SFAS No. 140 to eliminate the prohibition on a qualifying special-purpose entity from holding a derivative financial instrument that pertains to a beneficial interest other than another derivative financial instrument. SFAS No. 155 is effective for all financial instruments acquired or issued after the beginning of the first fiscal year that begins after September 15, 2006. The Company is currently evaluating the effect the adoption of SFAS No. 155 will have on its financial position or results of operations.

11

In March 2006, the FASB issued SFAS No. 156, "Accounting for Servicing of Financial Assets, an amendment of FASB Statement No. 140." SFAS No. 156 requires an entity to recognize a servicing asset or liability each time it undertakes an obligation to service a financial asset by entering into a servicing contract under a transfer of the servicer's financial assets that meets the requirements for sale accounting, a transfer of the servicer's financial assets to a qualified special-purpose entity in a guaranteed mortgage securitization in which the transferor retains all of the resulting securities and classifies them as either available-for-sale or trading securities in accordance with SFAS No. 115, "Accounting for Certain Investments in Debt and Equity Securities" and an acquisition or assumption of an obligation to service a financial asset that does not relate to financial assets of the servicer or its consolidated affiliates. Additionally, SFAS No. 156 requires all separately recognized servicing assets and servicing liabilities to be initially measured at fair value, permits an entity to choose either the use of an amortization or fair value method for subsequent measurements, permits at initial adoption a one-time reclassification of available-for-sale securities to trading securities by entities with recognized servicing rights and requires separate presentation of servicing assets and liabilities subsequently measured at fair value and additional disclosures for all separately recognized servicing assets and liabilities. SFAS No. 156 is effective for transactions entered into after the beginning of the first fiscal year that begins after September 15, 2006. The Company is currently evaluating the effect the adoption of SFAS No. 156 will have on its financial position or results of operations.

Edgar Filing: MEDIFAST INC - Form 10-Q

11. Revenue Recognition

Revenue is recognized for product sales upon shipment and passing of risk to the customer and when estimates of discounts, rebates, promotional adjustments, price adjustments, returns, and other potential adjustments are reasonably determinable, collection is reasonably assured and the Company has no further performance obligations. These estimates are presented in the financial statements as reductions to net revenues and accounts receivable. Estimated sales returns, allowances and discounts are provided for.

Outbound shipping charges to customers and outbound shipping-related costs are netted and included in "cost of sales."

Returns - Consistent with industry practice, the Company maintains a return policy that allows its customers to return product within a specified period (30 days). Because the period of payment generally approximates the period revenue was originally recognized, refunds are recorded as a reduction of revenue when paid. The Company's estimate for returns is based upon its historical experience with actual returns. While such experience has allowed for reasonable estimation in the past, history may not always be an accurate indicator of future returns. The Company continually monitors its estimates for returns and makes adjustments when it believes that actual product returns may differ from the established accruals.

12

MANAGEMENT DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Except for the historical information contained herein, this Report on Form 10-Q contains certain forward-looking statements that involve substantial risks and uncertainties. When used in this Report, the words "anticipate," "believe," "estimate," "expect" and similar expressions, as they relate to Medifast, Inc. or its management, are intended to identify such forward-looking statements. The Company's actual results, performance or achievements could differ materially from the results expressed in, or implied by, these forward-looking statements. Accordingly, there is no assurance that the results in the forward-looking statements will be achieved.

GENERAL

SIX MONTHS ENDED JUNE 30, 2006 AND JUNE 30, 2005

Revenue: Revenue increased to \$39.1 million for the first six months of 2006 as compared to \$18.9 million for the first six months of 2005, an increase of \$20.2 million or 107%. The direct marketing sales channel accounted for 60% of total revenue, Take Shape for Life 30%, doctors 5%, and clinics 5%. As compared to the first 6 months of 2005, the direct marketing sales channel, which is fueled primarily by consumer advertising, increased revenues by approximately 160%. Take Shape for Life sales, which are fueled by person-to-person recruiting and support increased by 70% year-over-year. In the first 6 months of 2006, the doctor channel increased sales by 25% and the clinics increased sales by 90% as compared to the six months ended June 30, 2005.

The growth in revenue is primarily the result of an increased advertising campaign in 2006. The Company has expanded into additional print media and national cable and network TV spots. The Company also continues to expand its presence on the web through affiliate advertising and paid search on sites, such

Edgar Filing: MEDIFAST INC - Form 10-Q

as google and yahoo. Additionally, the Take Shape for Life network continues to grow as the sales network expands. The Company continues to create new tools and training materials for health advisors and is in the final stages of implementing a new IT platform. The new software will empower the Take Shape for Life direct selling model by implementing the infrastructure and tools that are critical in supporting health advisors to grow their business.

Due to the significant growth in the first quarter of 2006, Medifast, Inc. began exploring third party over-sourcing capabilities in both the call center and product production. The Company began using an outsourced call center for overflow call volume in late April. Also, an outsourced production facility was employed in late April to produce certain high volume products in order to increase our inventory levels for anticipated future growth. The Company believes that these over-sourcing capabilities will provide the Company with the scalability necessary to seamlessly handle increased demands as the business continues to grow.

Costs and Expenses: Cost of revenue increased \$4.9 million to \$9.6 million in the first six months of 2006 from \$4.7 million in 2005. As a percentage of sales, gross margin increased to 75.4% for the first six months of 2006 as compared to 75.1% for the first six months of 2005. The slight increase in gross margin is primarily due to decreased raw material costs as a result of increased volume discounts.

Advertising expense for the first six months of 2006 was approximately \$7 million as compared to approximately \$2 million in the first six months of 2005, an increase of \$5 million. The increased marketing was spent primarily for TV advertising and print media. The Company continues to test and analyze which TV clusters and print media provide the lowest cost to acquire a customer. This testing will allow us to spend our advertising dollars most effectively as we plan on increasing our advertising budget in the first quarter of 2007.

13

Other Income/Expense: Stock compensation expense for the first six months of 2006 was \$181,000 as compared to \$0 in 2005. This expense represents the vesting of share-based compensation to key executives over five and six year terms. The Company has reviewed unvested options and concluded that the effects of FASB 123R are immaterial.

On January 17, 2006 the assets of Consumer Choice Systems, a division of Medifast, Inc., were sold to a former Board member. The promissory note calls for monthly principal only payments over a 10-year term. Therefore, when imputing an interest rate on the loan, a \$323,000 loss had to be realized due to the difference in the present value of the note receivable compared to the amount realizable over 10-years. This is a one-time loss that will not affect any future periods.

Income taxes: For the first six months of 2006 we recorded \$2 million in income tax expense, which represents an annual effective rate of 39%. The estimated annual effective tax rate differed from the U.S. federal statutory rate of 35% due to state income taxes. For the first six months of 2005, we recorded income tax expense of \$758,000 which reflected an estimated annual effective tax rate of 38%.

Net income: Net income increased to \$3.2 million in the first six months of 2006 as compared to \$1.3 million in the first six months of 2005, which reflected an increase of \$1.9 million or 146%. The increase in net income is due to an increase in sales offset by increased selling, general, and administrative

Edgar Filing: MEDIFAST INC - Form 10-Q

expenses, that primarily consist of increased advertising and commissions paid to Take Shape for Life health advisors.

THREE MONTHS ENDED JUNE 30, 2006 AND JUNE 30, 2005

Revenue: Revenue increased to \$20 million in the second quarter of 2006 as compared to \$10.6 million in the second quarter of 2005, an increase of \$9.4 million or 89%. The direct marketing sales channel accounted for 60% of total revenue, Take Shape for Life 30%, doctors 5%, and clinics 5%. In the comparable period in 2005, the direct marketing sales channel, which is fueled primarily by consumer advertising increased revenues by approximately 120%. Take Shape for Life sales, which are fueled by person-to-person recruiting and support increased by approximately 60% year-over-year. For the three-months ended June 30, 2006, the doctor channel increased sales by 25% and the clinics increased sales by approximately 70% as compared to the second quarter of 2005.

The growth in revenue is primarily the result of an increased advertising campaign in 2006. The Company has expanded into additional print media and national cable and network TV spots. During the second quarter the Company did extensive testing of TV and print media in preparation for an increased advertising budget in 2007. The testing caused the cost to acquire a customer to increase, however, the Company feels this testing is necessary in order to effectively spend increased advertising dollars in the first quarter of 2007.

Costs and Expenses: Cost of revenue increased \$2.3 million to \$4.9 million in the second quarter of 2006 from \$2.6 million in the second quarter 2005. As a percentage of sales, gross margin increased to 75.7% in the second quarter of 2006 as compared to 75.1% in the second quarter of 2005. The slight increase in gross margin is primarily due to decreased raw material costs as a result of increased volume discounts.

Advertising expense in the second quarter of 2006 was approximately \$4.5 million as compared to approximately \$1.2 million in the second quarter of 2005. The increased marketing was spent primarily for TV advertising and print. The Company spent approximately \$2 million in television and print media for testing the acquisition of customers slightly outside of its' current core demographic. The results of this testing, although increasing the overall cost to acquire, were very informative in planning for increased future advertising spending. The Company believes that the data received through the customer responses and feedback, along with some minimal adjustments to advertisement placement and design will allow the new ad venues to become viable customer acquisition tools for the expected future advertising campaigns.

14

Other Income/Expense: Stock compensation expense for second quarter of 2006 was \$164,000 as compared to \$0 in 2005. This amount will be consistent for the remainder of 2006. This expense represents the vesting of share-based compensation to key executives over five and six year terms. The Company has reviewed unvested options and concluded that the effects of FASB 123R are immaterial.

Income taxes: In the second quarter of 2006 we recorded \$884,000 in income tax expense, which represents an annual effective rate of 39%. The estimated annual effective tax rate differed from the U.S. federal statutory rate of 35% due to state income taxes. In the second quarter of 2005, we recorded income tax expense of \$411,000 which reflected an estimated annual effective tax rate of 35%.

Edgar Filing: MEDIFAST INC - Form 10-Q

Net income: Net income increased to \$1.5 million in the second quarter of 2006 as compared to \$753,000 in the second quarter of 2005, which reflected an increase of \$747,000 or 99%. The increase in net income is due to an increase in sales offset by increased selling, general, and administrative expenses, that primarily consist of increased advertising and commissions paid to Take Shape for Life health advisors.

LIQUIDITY AND CAPITAL RESOURCES

The Company had stockholders' equity of \$25,530,000 and working capital of \$12,025,000 on June 30, 2006 compared with \$20,602,000 and \$8,991,000 at June 30, 2005, respectively. The \$4,928,000 net increase in stockholder's equity and the \$3,034,000 net increase in working capital reflects the increased profitability of the Company. The Company's cash position increased from \$1.5 million at December 31, 2005 to \$2.5 million at June 30, 2006 which is attributable to the increased sales and a decrease in expenses as compared to total sales offset by additional cash outlays for infrastructure to handle additional sales growth. On June 30, 2006 the Company's current ratio was 3.6 to 1.

SEASONALITY

The Company's weight management products and programs have historically been subject to seasonality. Traditionally the holiday season in November/December of each year is considered poor for diet control products and services. January and February generally show increases in sales, as these months are considered the commencement of the "diet season." In 2005 and into 2006 seasonality has not been a significant factor. This is largely due to the increase in the consumer's awareness of the overall health and nutritional benefits accompanied with the use of the Company's product line. As consumers continue to increase their association of nutritional weight loss programs with overall health, seasonality will continue to decrease.

INFLATION

To date, inflation has not had a material effect on the Company's business.

ITEM 5. OTHER INFORMATION

Litigation:

There was no material pending or threatened litigation as of 6/30/06.

Long-Term Employment Contracts

The Board of Directors of Medifast, Inc. is in the process of implementing a management succession plan which will take place over the next 24 months. In doing so, they have had 3 key executive officers sign 6-year employment contracts to ensure that there will be minimal turnover in selected key management positions. The Executives associated with this succession plan include Michael S. McDevitt, President and Chief Financial Officer, Margaret MacDonald, VP of Operations and Brendan Connors, CPA, VP of Finance. Bradley T.

Edgar Filing: MEDIFAST INC - Form 10-Q

MacDonald, the Executive Chairman of the Board of Directors and CEO has signed and executed a new 5 year employment agreement as the Executive Chairman of the Board of Directors and will provide on-going executive mentoring, financial and M&A advice, and new business development for the Company.

On February 8, 2006, three executive officers of the Company signed 6-year employment contracts. The officers received shares of common stock in varying amounts totaling 380,000 shares at \$6.25 per share that will be vested over 6 years. In addition, Bradley T. MacDonald, Chairman and CEO signed a new 5-year employment agreement and was granted 100,000 stock options at \$6.25 that will vest over 5 years beginning on February 8, 2007.

Planned stock sale

In order to diversify his retirement portfolio which is largely invested in Medifast stock, Bradley MacDonald, Chairman and CEO is planning on selling approximately 200,000 shares of Medifast stock over the next 12 months. After the sale, he will still beneficially own approximately 900,000 shares of Medifast, Inc. common stock, which would currently represent about 7% of the outstanding shares. After this transaction, Mr. MacDonald will still be the largest shareholder of Medifast.

Earnings Per Share: The Company follows the provisions of Statement of Financial Accounting Standards No. 128, "Earnings Per Share." The calculation of basic and diluted earnings per share ("EPS") is reflected on the accompanying Consolidated Statement of Operations.

Code of Ethics: In September 2002, the Company implemented a Code of Ethics by which directors, officers and employees commit and undertake to personal and corporate growth, dedicate themselves to excellence, integrity and responsiveness to the marketplace, and work together to enhance the value of the Company for the shareholders, vendors, and customers.

Trading Policy: In March 2003, the Company implemented a Trading Policy whereby if a director, officer or employee has material non-public information relating to the Company, neither that person nor any related person may buy or sell securities of the Company or engage in any other action to take advantage of, or pass on to others, that information. Additionally, insiders may purchase or sell MED securities if such purchase or sale is made within 30 days after an earnings or special announcement to include the 10-K, 10-Q and 8-K in order to insure that investors have available the same information necessary to make investment decisions as insiders.

16

Internal Control Policy: As of June 30, 2006, the Company's management, with the participation of the Chief Executive Officer and the President, performed an evaluation of the effectiveness of the design and operation of the Company's disclosure controls and procedures pursuant to Exchange Act Rule 13a-15. Based on that evaluation, the Chief Executive Officer and the President have concluded that the design and operation of these disclosure controls and procedures were effective as of the end of the period covered by this report. In connection with this evaluation, no change in the Company's internal control over financial reporting was identified that occurred during the period covered by this report that has materially affected, or is reasonably likely to affect the Company's internal control over financial reporting.

Forward Looking Statements: Some of the information presented in this quarterly report constitutes forward-looking statements within the meaning of the private

Edgar Filing: MEDIFAST INC - Form 10-Q

Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about management's expectations for fiscal year 2003 and beyond, are forward-looking statements and involve various risks and uncertainties. Although the Company believes that its expectations are based on reasonable assumptions within the bounds of its knowledge, there can be no assurance that actual results will not differ materially from the Company's expectations. The Company cautions investors not to place undue reliance on forward-looking statements which speak only to management's experience on this date.

17

Index to Exhibits

Exhibit Number	Description of Exhibit
31.1	Certification of Chief Executive Officer pursuant to Item 601(b) (31) of Regulation S-K, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2	Certification of Chief Financial Officer pursuant to Item 601(b) (31) of Regulation S-K, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1	Certification of Chief Executive Officer and Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

18